STAHLBERG JAN

10% owner Jan Stahlberg purchases 1,061,277 shares ($7.6M) across 7 days at blended $7.19; now holds 8,825,742 shares (+13.7%)

Jan Stahlberg, a 10% owner at DiaMedica Therapeutics, executed 7 separate purchases totaling 1,061,277 shares for $7,631,469.23 between November 17–25, 2025, at prices ranging from $6.52 to $8.57. This represents a 13.7% increase in his holdings and occurs within the context of a 30-day stock price appreciation of +48.0% and a 90-day rise of +21.5%, despite the company reporting negative fundamentals (net income of $-8,620,000.00 for the most recent fiscal year). His prior 5 purchases at this same ticker over August 2025 all posted positive 90-day returns, with a perfect timing pattern; however, this current multi-day accumulation introduces questions about valuation—the company is unprofitable with quarterly revenue of only $500,000.00 yet maintains a market cap of $456,198,365.64, and the current price of $8.76 sits near the 52-week high of $9.12. The series of purchases at steadily escalating prices (with a +21.5% gain over just 7 calendar days from first to last transaction) diverges from his August pattern and warrants examination of whether this reflects conviction in a turnaround or execution against prior commitment.

10% Owner STAHLBERG JAN buys 1,000,000 shares ($5.96 blended avg) across 9 transactions; holdings rise to 7.76M shares (+14.8%)

STAHLBERG JAN, a 10% owner of DiaMedica Therapeutics, executed 9 separate open-market purchases totaling 1,000,000 shares for $5,958,106.80 between August 13–27, 2025, at a blended average price of $5.96. This represents a substantial 14.8% increase to his post-transaction holdings of 7.76M shares. The company remains unprofitable (net income of $-7.7M in its most recent full fiscal year) with minimal revenue ($500,000.00 in the latest quarter), yet the insider has demonstrated a consistent pattern of accumulation: his prior trade at this same ticker on 2025-07-23 achieved a 30-day return of +74.6%, and his 2024-06-28 purchase at DMAC yielded a 90-day return of +72.0%. Across his broader cross-ticker history, he has maintained a 100% win rate at the 90-day mark with an average return of +72.0%. The current price of $5.37 stands 19.2% below the 52-week high but 29.7% above the 90-day baseline, indicating recent upward momentum that followed his prior July transaction.

10% Owner Jan Stahlberg buys 1,542,857 shares of DMAC at $3.50 for $5.4M, increasing stake 29.5%; 2 other insiders bought within 14 days

Stahlberg, a 10% owner, purchased 1,542,857 shares at $3.50 on 2025-07-23, increasing his holdings from 5,221,608 to 6,764,465 shares. This follows his prior DMAC purchase on 2024-06-28, which posted 90-day gains of 72.0%. Current price of $5.05 is -24.1% from the 52-week high of $6.65 but reflects 30-day appreciation of 27.8%. The company is unprofitable with -$7.7M net income in its most recent fiscal year and only $500,000 in latest quarterly revenue. A cluster pattern exists: 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation despite fundamentals showing significant losses.

10% owner Stahlberg purchases 1,200,000 shares of DMAC at $2.50 for $3,000,000.00, expanding stake to 5,221,608 shares.

Stahlberg Jan, a 10% owner, acquired 1,200,000 shares (1.20M shares) at $2.50 on 2024-06-28 for a total of $3,000,000.00, increasing post-transaction holdings to 5,221,608 shares (5.22M shares) from 4,021,608 shares (4.02M shares), a net increase of +29.8% versus pre-transaction holdings. The transaction occurred when the stock was trading -33.0% from its 52-week high of $4.40, and the company continues to face fundamental challenges: latest quarterly revenue was $500,000.00 ($500.0K) while net income was negative at $-5,151,000.00 ($-5.2M), with the company unprofitable over its most recent full fiscal year. The size and timing of this substantial acquisition by an existing majority shareholder merit close examination of whether this reflects conviction in a recovery thesis or represents obligations tied to earlier commitments given the company's ongoing losses and compressed valuation relative to recent trading ranges.